Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
THOR's Cash to Debt is ranked higher than
93% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. THOR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
THOR' s 10-Year Cash to Debt Range
Min: 0.94  Med: 41.05 Max: No Debt
Current: No Debt
Equity to Asset 0.84
THOR's Equity to Asset is ranked higher than
82% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. THOR: 0.84 )
Ranked among companies with meaningful Equity to Asset only.
THOR' s 10-Year Equity to Asset Range
Min: 0.39  Med: 0.80 Max: 0.91
Current: 0.84
0.39
0.91
Interest Coverage 2914.08
THOR's Interest Coverage is ranked lower than
51% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. THOR: 2914.08 )
Ranked among companies with meaningful Interest Coverage only.
THOR' s 10-Year Interest Coverage Range
Min: 2.02  Med: 6457.04 Max: 9999.99
Current: 2914.08
2.02
9999.99
F-Score: 5
Z-Score: 18.50
M-Score: -2.88
WACC vs ROIC
2.66%
11.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 12.90
THOR's Operating margin (%) is ranked higher than
78% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. THOR: 12.90 )
Ranked among companies with meaningful Operating margin (%) only.
THOR' s 10-Year Operating margin (%) Range
Min: -82.51  Med: 5.55 Max: 27.01
Current: 12.9
-82.51
27.01
Net-margin (%) 9.07
THOR's Net-margin (%) is ranked higher than
75% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. THOR: 9.07 )
Ranked among companies with meaningful Net-margin (%) only.
THOR' s 10-Year Net-margin (%) Range
Min: -77.49  Med: 4.31 Max: 16.92
Current: 9.07
-77.49
16.92
ROE (%) 6.54
THOR's ROE (%) is ranked higher than
59% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.14 vs. THOR: 6.54 )
Ranked among companies with meaningful ROE (%) only.
THOR' s 10-Year ROE (%) Range
Min: -36.67  Med: 4.12 Max: 45.42
Current: 6.54
-36.67
45.42
ROA (%) 5.50
THOR's ROA (%) is ranked higher than
69% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: -0.22 vs. THOR: 5.50 )
Ranked among companies with meaningful ROA (%) only.
THOR' s 10-Year ROA (%) Range
Min: -25  Med: 2.42 Max: 38.18
Current: 5.5
-25
38.18
ROC (Joel Greenblatt) (%) 40.00
THOR's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. THOR: 40.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
THOR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -198.59  Med: 26.28 Max: 86.09
Current: 40
-198.59
86.09
Revenue Growth (3Y)(%) 7.60
THOR's Revenue Growth (3Y)(%) is ranked higher than
66% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. THOR: 7.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
THOR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.1  Med: 14.20 Max: 71.9
Current: 7.6
-2.1
71.9
EBITDA Growth (3Y)(%) -11.60
THOR's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. THOR: -11.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
THOR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -11.6  Med: 5.25 Max: 133.5
Current: -11.6
-11.6
133.5
EPS Growth (3Y)(%) -9.50
THOR's EPS Growth (3Y)(%) is ranked lower than
61% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. THOR: -9.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
THOR' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.2  Med: 16.90 Max: 196.2
Current: -9.5
-66.2
196.2
» THOR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

THOR Guru Trades in Q3 2014

Joel Greenblatt 970,893 sh (+140.96%)
Manning & Napier Advisors, Inc 1,575,340 sh (+138.26%)
Paul Tudor Jones 33,802 sh (+86.36%)
Chuck Royce 348,300 sh (-44.08%)
Jim Simons 132,939 sh (-85.61%)
» More
Q4 2014

THOR Guru Trades in Q4 2014

Manning & Napier Advisors, Inc 1,857,440 sh (+17.91%)
Joel Greenblatt Sold Out
Chuck Royce Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q1 2015

THOR Guru Trades in Q1 2015

Manning & Napier Advisors, Inc 1,219,930 sh (-34.32%)
» More
Q2 2015

THOR Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 1,066,760 sh (-12.56%)
» More
» Details

Insider Trades

Latest Guru Trades with THOR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 82.69
THOR's P/E(ttm) is ranked lower than
87% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 28.40 vs. THOR: 82.69 )
Ranked among companies with meaningful P/E(ttm) only.
THOR' s 10-Year P/E(ttm) Range
Min: 19.97  Med: 57.59 Max: 541.28
Current: 82.69
19.97
541.28
Forward P/E 42.37
THOR's Forward P/E is ranked lower than
80% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.26 vs. THOR: 42.37 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 82.80
THOR's PE(NRI) is ranked lower than
86% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 28.30 vs. THOR: 82.80 )
Ranked among companies with meaningful PE(NRI) only.
THOR' s 10-Year PE(NRI) Range
Min: 20.06  Med: 57.74 Max: 527.75
Current: 82.8
20.06
527.75
P/B 5.25
THOR's P/B is ranked lower than
72% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. THOR: 5.25 )
Ranked among companies with meaningful P/B only.
THOR' s 10-Year P/B Range
Min: 1.42  Med: 2.95 Max: 5.26
Current: 5.25
1.42
5.26
P/S 7.49
THOR's P/S is ranked lower than
77% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. THOR: 7.49 )
Ranked among companies with meaningful P/S only.
THOR' s 10-Year P/S Range
Min: 2.7  Med: 4.41 Max: 7.51
Current: 7.49
2.7
7.51
PFCF 35.32
THOR's PFCF is ranked lower than
60% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 30.88 vs. THOR: 35.32 )
Ranked among companies with meaningful PFCF only.
THOR' s 10-Year PFCF Range
Min: 12.79  Med: 28.03 Max: 2111
Current: 35.32
12.79
2111
POCF 32.59
THOR's POCF is ranked lower than
70% of the 149 Companies
in the Global Medical Devices industry.

( Industry Median: 21.63 vs. THOR: 32.59 )
Ranked among companies with meaningful POCF only.
THOR' s 10-Year POCF Range
Min: 11.81  Med: 25.69 Max: 175.92
Current: 32.59
11.81
175.92
EV-to-EBIT 53.27
THOR's EV-to-EBIT is ranked lower than
81% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 21.84 vs. THOR: 53.27 )
Ranked among companies with meaningful EV-to-EBIT only.
THOR' s 10-Year EV-to-EBIT Range
Min: -3731.1  Med: 25.40 Max: 287.2
Current: 53.27
-3731.1
287.2
PEG 82.80
THOR's PEG is ranked lower than
95% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 3.42 vs. THOR: 82.80 )
Ranked among companies with meaningful PEG only.
THOR' s 10-Year PEG Range
Min: 0.54  Med: 3.17 Max: 512.38
Current: 82.8
0.54
512.38
Shiller P/E 63.03
THOR's Shiller P/E is ranked lower than
76% of the 94 Companies
in the Global Medical Devices industry.

( Industry Median: 30.75 vs. THOR: 63.03 )
Ranked among companies with meaningful Shiller P/E only.
THOR' s 10-Year Shiller P/E Range
Min: 23.74  Med: 72.26 Max: 427.2
Current: 63.03
23.74
427.2
Current Ratio 6.00
THOR's Current Ratio is ranked higher than
80% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. THOR: 6.00 )
Ranked among companies with meaningful Current Ratio only.
THOR' s 10-Year Current Ratio Range
Min: 1.9  Med: 7.65 Max: 13.05
Current: 6
1.9
13.05
Quick Ratio 5.05
THOR's Quick Ratio is ranked higher than
80% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. THOR: 5.05 )
Ranked among companies with meaningful Quick Ratio only.
THOR' s 10-Year Quick Ratio Range
Min: 1.1  Med: 6.28 Max: 11.18
Current: 5.05
1.1
11.18
Days Inventory 149.90
THOR's Days Inventory is ranked lower than
57% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 131.01 vs. THOR: 149.90 )
Ranked among companies with meaningful Days Inventory only.
THOR' s 10-Year Days Inventory Range
Min: 65.17  Med: 186.95 Max: 330.47
Current: 149.9
65.17
330.47
Days Sales Outstanding 54.16
THOR's Days Sales Outstanding is ranked higher than
72% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.21 vs. THOR: 54.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
THOR' s 10-Year Days Sales Outstanding Range
Min: 25.54  Med: 65.34 Max: 91.69
Current: 54.16
25.54
91.69

Valuation & Return

vs
industry
vs
history
Price/Net Cash 28.25
THOR's Price/Net Cash is ranked lower than
68% of the 105 Companies
in the Global Medical Devices industry.

( Industry Median: 14.23 vs. THOR: 28.25 )
Ranked among companies with meaningful Price/Net Cash only.
THOR' s 10-Year Price/Net Cash Range
Min: 4.25  Med: 18.45 Max: 1087.5
Current: 28.25
4.25
1087.5
Price/Net Current Asset Value 11.68
THOR's Price/Net Current Asset Value is ranked lower than
69% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 6.53 vs. THOR: 11.68 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
THOR' s 10-Year Price/Net Current Asset Value Range
Min: 2.61  Med: 10.29 Max: 362.5
Current: 11.68
2.61
362.5
Price/Tangible Book 8.94
THOR's Price/Tangible Book is ranked lower than
74% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. THOR: 8.94 )
Ranked among companies with meaningful Price/Tangible Book only.
THOR' s 10-Year Price/Tangible Book Range
Min: 2.33  Med: 6.42 Max: 310.71
Current: 8.94
2.33
310.71
Price/Projected FCF 2.39
THOR's Price/Projected FCF is ranked lower than
59% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. THOR: 2.39 )
Ranked among companies with meaningful Price/Projected FCF only.
THOR' s 10-Year Price/Projected FCF Range
Min: 1.06  Med: 2.20 Max: 12.75
Current: 2.39
1.06
12.75
Price/DCF (Earnings Based) 2.91
THOR's Price/DCF (Earnings Based) is ranked lower than
88% of the 16 Companies
in the Global Medical Devices industry.

( Industry Median: 1.69 vs. THOR: 2.91 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.69
THOR's Price/Median PS Value is ranked lower than
77% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 1.14 vs. THOR: 1.69 )
Ranked among companies with meaningful Price/Median PS Value only.
THOR' s 10-Year Price/Median PS Value Range
Min: 0.7  Med: 1.11 Max: 23.14
Current: 1.69
0.7
23.14
Price/Graham Number 5.61
THOR's Price/Graham Number is ranked lower than
78% of the 136 Companies
in the Global Medical Devices industry.

( Industry Median: 2.46 vs. THOR: 5.61 )
Ranked among companies with meaningful Price/Graham Number only.
THOR' s 10-Year Price/Graham Number Range
Min: 1.87  Med: 3.71 Max: 12.72
Current: 5.61
1.87
12.72
Earnings Yield (Greenblatt) (%) 1.87
THOR's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. THOR: 1.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
THOR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.3  Med: 3.30 Max: 9.6
Current: 1.87
0.3
9.6
Forward Rate of Return (Yacktman) (%) -3.11
THOR's Forward Rate of Return (Yacktman) (%) is ranked lower than
66% of the 99 Companies
in the Global Medical Devices industry.

( Industry Median: 4.14 vs. THOR: -3.11 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
THOR' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -7.2  Med: 8.60 Max: 45.7
Current: -3.11
-7.2
45.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:TL1.Germany,
Thoratec Corporation incorporated in the State of California in 1976 provides mechanical circulatory support with a product portfolio to treat the full range of clinical needs for advanced heart failure patients. It develops, manufactures and markets proprietary medical devices used for circulatory support. Following the sale of ITC in 2010, the Company has one operating segment: Cardiovascular group. This segment is organized and operates to develop and manufacture mechanical circulatory products to support the cardiovascular systems of humans. The Company's VAD products primarily serve patients suffering from late-stage HF. HF is a chronic disease that occurs when degeneration of the heart muscle reduces the pumping power of the heart, causing the heart to become too weak to pump blood at a level sufficient to meet the body's demands. Hospitals that perform open heart surgery and heart transplants are the potential customers for its Thoratec and HeartMate products. The Company estimates that it sells into 293 of these centers. According to the Company's estimates, it is in approximately 149 centers in the United States and 144 centers internationally. Competition from medical device companies and medical device divisions of healthcare companies, pharmaceutical companies and gene- and cell-based therapies is intense and is expected to increase. It therefore continues to expect new competitors both from the pharmacological and the medical device space. Among the medical device competitors are Aachen Innovative Solutions GmbH, AbioMed, Inc., Berlin Heart GmbH, HeartWare International Inc., Jarvik Heart, Inc., Maquet Cardiovascular, LLC (a division of Getinge AB), MicroMed Technology, Inc., Sun Medical Technology Research Corporation, SynCardia Systems, Inc., and Terumo Heart, Inc. All of the Company's proposed products will require regulatory approval prior to commercialization. In particular, medical devices are subject to rigorous pre-clinical testing as a condition of approval by the FDA and by similar authorities in foreign countries.
» More Articles for THOR

Headlines

Articles On GuruFocus.com
5-year lows: Thoratec Corp, Brady Corp, General Cable Corp, and UTi Worldwide Inc. Aug 25 2014 
5-year lows: Mack-Cali Realty Corp, Thoratec Corp, Brady Corp, and EXCO Resources Inc. Aug 10 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Weekly Guru Bargains Highlights: CSTR, VRX, SAY, THOR, BVN Feb 12 2011 
Weekly Guru Bargains Highlights: CSTR, VRX, SAY, THOR, BVN Feb 12 2011 
Weekly Guru Bargains Highlights: SVU, MSI, THOR, JNY, AMLN Jan 23 2011 
Weekly Guru Bargains Highlights: DF, CLWR, THOR, VRX, ASIA Dec 26 2010 
Weekly Guru Bargains Highlights: TFSL, THOR, CISG, VRX, DLR Dec 18 2010 
Weekly Guru Bargains Highlights: THOR, SKX, AMLN, SAY, JOE Dec 12 2010 

More From Other Websites
Thoratec Sale May Be Precursor of More Cardiac Industry M&A Jul 30 2015
St. Jude Buying Thoratec Could Resusitate Medtech M&As Jul 30 2015
THORATEC CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Jul 27 2015
THOR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of... Jul 27 2015
Lifshitz & Miller Law Firm Announces Investigation of Celladon Corporation, Edison International,... Jul 24 2015
Thoratec Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC... Jul 24 2015
Converging On A Heartthrob Market Jul 24 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Thoratec Corp. of Commencement of... Jul 24 2015
Ryan & Maniskas, LLP Announces Investigation of Thoratec Corp. Jul 24 2015
St. Jude to Acquire Thoratec for $3.4B: Potent Combination? - Analyst Blog Jul 23 2015
Thoratec Stockholders Encouraged to Contact Securities Law Firm about Takeover Jul 23 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Thoratec Corp. of Commencement of... Jul 23 2015
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Thoratec Corp.... Jul 23 2015
THORATEC CORP. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP... Jul 23 2015
Why You Should Hold Your Bets On the St. Jude Medical, Inc. (STJ) and Thoratec Corporation (THOR)... Jul 23 2015
BMO Capital Downgrades St. Jude Medical On 'Less Compelling' Risk/Reward Jul 23 2015
St. Jude's $3.4B Thoratec deal would be its biggest buy yet Jul 23 2015
Thoratec downgraded by Wells Fargo Jul 23 2015
St. Jude Medical to Buy Thoratec for $3.4 Billion Jul 22 2015
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Thoratec Corporation... Jul 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK